Search Tag: IRX-2

Pharmacy Management

2015 23 Jan

Phase 2B trials of a generic fast-tracked immunity-boosting cancer therapeutic IRX-2 will be conducted after the biotech company IRX Therapeutics has successfully raised $31.6 million to finance these trials. The randomised head and neck cancer trials will include 200 patients and will be conducted in clinical centres across the US and Western Europe....Read more